Recurrent thromboembolism in a patient with beta-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations

Blood Coagul Fibrinolysis. 2002 Jul;13(5):461-3. doi: 10.1097/00001721-200207000-00012.

Abstract

Double heterozygosity for factor V R506Q and prothrombin G20210A mutations was identified in a 24-year-old man with beta-thalassemia major. The patient experienced a first thrombotic event at the age of 19 years and three recurrent thromboses in a short time interval, the third occurring while the patient was receiving long-term anticoagulant treatment. This case suggests that patients with major thalassemia and congenital thrombophilic mutations need intensive and long-lasting anticoagulant treatment. Thus, even if thrombotic events could be explained by a hypercoagulable state observed in patients with major thalassemia, after a first thrombotic event has occurred these patients should be screened for acquired and congenital thrombophilia.

Publication types

  • Case Reports

MeSH terms

  • 3' Untranslated Regions / genetics
  • Activated Protein C Resistance / complications*
  • Activated Protein C Resistance / genetics
  • Adult
  • Anticoagulants / therapeutic use
  • Aspirin / therapeutic use
  • Factor V / genetics*
  • Genetic Predisposition to Disease
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Heterozygote
  • Humans
  • Male
  • Popliteal Vein
  • Prothrombin / genetics*
  • Pulmonary Embolism / drug therapy
  • Pulmonary Embolism / etiology*
  • Recurrence
  • Saphenous Vein
  • Splenectomy
  • Thrombophilia / genetics*
  • Thrombophlebitis / drug therapy
  • Thrombophlebitis / etiology*
  • beta-Thalassemia / complications*
  • beta-Thalassemia / genetics

Substances

  • 3' Untranslated Regions
  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • factor V Leiden
  • Factor V
  • Prothrombin
  • Aspirin